| Clinical data | |
|---|---|
| Other names | ZK-230211; BAY 86-5044; ZK-PRA; 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one |
| Routes of administration | Oral |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.190.674 |
| Chemical and physical data | |
| Formula | C28H29F5O3 |
| Molar mass | 508.529 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lonaprisan (INN,USAN) (developmental code namesZK-230211,BAY 86-5044,ZK-PRA) is asynthetic,steroidalantiprogestogen which was under development byBayer HealthCare Pharmaceuticals for the treatment ofendometriosis,dysmenorrhea, andbreast cancer but was discontinued.[1][2][3] It is apotent and highlyselectivesilent antagonist of theprogesterone receptor (PR).[2][3][4] The drug reachedphase IIclinical trials prior to its discontinuation.[1]
Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |